JP2024521092A5 - - Google Patents
Info
- Publication number
- JP2024521092A5 JP2024521092A5 JP2023571661A JP2023571661A JP2024521092A5 JP 2024521092 A5 JP2024521092 A5 JP 2024521092A5 JP 2023571661 A JP2023571661 A JP 2023571661A JP 2023571661 A JP2023571661 A JP 2023571661A JP 2024521092 A5 JP2024521092 A5 JP 2024521092A5
- Authority
- JP
- Japan
- Prior art keywords
- target
- salt
- compound
- moi
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163190703P | 2021-05-19 | 2021-05-19 | |
| US63/190,703 | 2021-05-19 | ||
| PCT/US2022/030070 WO2022246086A1 (en) | 2021-05-19 | 2022-05-19 | Antibody drug conjugates using mates technology for delivering cytotoxic agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024521092A JP2024521092A (ja) | 2024-05-28 |
| JP2024521092A5 true JP2024521092A5 (https=) | 2025-05-26 |
Family
ID=84141792
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023571661A Pending JP2024521092A (ja) | 2021-05-19 | 2022-05-19 | 細胞傷害性薬剤を送達するためのｍａｔｅｓ技術を使用する抗体薬物コンジュゲート |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20250108124A1 (https=) |
| EP (1) | EP4340859A4 (https=) |
| JP (1) | JP2024521092A (https=) |
| KR (1) | KR20240012381A (https=) |
| CN (1) | CN117412761A (https=) |
| AU (1) | AU2022277698A1 (https=) |
| BR (1) | BR112023023525A2 (https=) |
| CA (1) | CA3219550A1 (https=) |
| IL (1) | IL307884A (https=) |
| MX (1) | MX2023013270A (https=) |
| PH (1) | PH12023553153A1 (https=) |
| WO (1) | WO2022246086A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2023013274A (es) * | 2021-05-17 | 2023-11-30 | Biohaven Therapeutics Ltd | Composiciones que incluyen potenciadores de tratamientos conjugados. |
| EP4704910A1 (en) * | 2023-04-23 | 2026-03-11 | Biohaven Therapeutics Ltd. | Antibody-drug conjugates for delivering cytotoxic agents |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2478912B1 (en) * | 2003-11-06 | 2016-08-31 | Seattle Genetics, Inc. | Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy |
| JP2009541275A (ja) * | 2006-06-22 | 2009-11-26 | ノボ・ノルデイスク・エー／エス | 二重特異性抗体の生産 |
| EP2497775A1 (en) * | 2011-03-11 | 2012-09-12 | Ruprecht-Karls-Universität Heidelberg | Ferrocene-based compounds and their use as ROS regulating prodrugs |
| CN102936281B (zh) * | 2012-10-25 | 2013-12-25 | 浙江大学 | 一种rTRAIL突变体及其海兔毒素偶联物 |
| EP3193940A1 (en) * | 2014-09-10 | 2017-07-26 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| AU2015339012B2 (en) * | 2014-10-31 | 2020-11-05 | Abbvie Biotherapeutics Inc. | Anti-CS1 antibodies and antibody drug conjugates |
| SI3280441T1 (sl) * | 2015-04-07 | 2022-01-31 | Alector Llc | Protitelesa anti-sortilin in metoda njihove uporabe |
| AU2018259856B2 (en) * | 2017-04-28 | 2025-05-01 | Ajinomoto Co., Inc. | Compound having substance that has affinity for soluble protein, cleavable moiety, and reactive group, or salt thereof |
| US10953107B2 (en) * | 2018-06-15 | 2021-03-23 | Trustees Of Boston University | Polypeptide compositions and methods for site-specific targeting of therapeutic agents |
| JP2022513198A (ja) * | 2018-12-10 | 2022-02-07 | ジェネンテック， インコーポレイテッド | Ｆｃ含有タンパク質への部位特異的コンジュゲーションのための光架橋性ペプチド |
| US20230028880A1 (en) * | 2019-07-03 | 2023-01-26 | Biohaven Therapeutics Ltd. | Cd38-binding agents and uses thereof |
| JP2023501720A (ja) * | 2019-11-18 | 2023-01-18 | クレオ ファーマシューティカルズ， インコーポレイテッド | 指向性コンジュゲーション技術 |
-
2022
- 2022-05-19 US US18/555,858 patent/US20250108124A1/en active Pending
- 2022-05-19 JP JP2023571661A patent/JP2024521092A/ja active Pending
- 2022-05-19 MX MX2023013270A patent/MX2023013270A/es unknown
- 2022-05-19 KR KR1020237039501A patent/KR20240012381A/ko active Pending
- 2022-05-19 AU AU2022277698A patent/AU2022277698A1/en active Pending
- 2022-05-19 WO PCT/US2022/030070 patent/WO2022246086A1/en not_active Ceased
- 2022-05-19 CN CN202280034208.8A patent/CN117412761A/zh active Pending
- 2022-05-19 BR BR112023023525A patent/BR112023023525A2/pt unknown
- 2022-05-19 EP EP22805492.0A patent/EP4340859A4/en active Pending
- 2022-05-19 CA CA3219550A patent/CA3219550A1/en active Pending
- 2022-05-19 PH PH1/2023/553153A patent/PH12023553153A1/en unknown
- 2022-05-19 IL IL307884A patent/IL307884A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023501720A5 (https=) | ||
| JP7708133B2 (ja) | 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩 | |
| ES2618832T3 (es) | Composición TNFR-FC estabilizada que comprende arginina | |
| JP6647208B2 (ja) | 抗ｉｌ−１７抗体、その生産および使用のための方法 | |
| CN102946858B (zh) | 含有免疫球蛋白Fc的多肽的液体制剂 | |
| JP6328648B2 (ja) | 新規薬物−タンパク質コンジュゲート | |
| JP2004248677A5 (https=) | ||
| CA3103151A1 (en) | Compound having affinity substance to antibody and bioorthogonal functional group, or salt thereof | |
| JP2024521092A5 (https=) | ||
| ATE454124T1 (de) | Rekombinante anti-cd30-antikörper und deren verwendungen | |
| EA200000331A1 (ru) | Фармацевтические композиции, содержащие белок плазмы | |
| JP2016513635A (ja) | 低濃度抗体製剤 | |
| JP2022518743A (ja) | 抗体－薬物コンジュゲート用のグリコシド含有ペプチドリンカー | |
| JP2020513019A5 (https=) | ||
| WO2021080008A1 (ja) | １価ｃｃａｐ生成物の製造方法 | |
| JP7605290B2 (ja) | 化合物またはその塩、およびそれらにより得られる抗体 | |
| JP2020509010A5 (https=) | ||
| JP2025512735A5 (https=) | ||
| JP2023511184A5 (https=) | ||
| JP2025124732A (ja) | 化合物またはその塩、およびそれらにより得られる抗体 | |
| JP2025111561A (ja) | 化合物またはその塩、およびそれらにより得られる抗体 | |
| JP2020189806A (ja) | 複合体 | |
| DE69833061T2 (de) | Aktivierte Peptide und deren Konjugate | |
| JP2024519814A5 (https=) | ||
| JP2024519031A5 (https=) |